Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations

Date

21 Oct 2023

Session

Poster session 20

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Urska Janzic

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

U. Janzic1, W. Shalata2, A. Agbarya3, R. Dziadziuszko4, K. Szymczak4, M. Jakopovic5, G. Mountzios6, A. Pluzanski7

Author affiliations

  • 1 Medical Oncology Department, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 - Golnik/SI
  • 2 Oncology Department, Soroka University Medical Center, 84101 - Beer Sheva/IL
  • 3 Oncology Department, Bnai Zion Medical Center, 31048 - Haifa/IL
  • 4 Department Of Oncology And Radiotherapy And Early Phase Clinical Trials Centre, Medical University of Gdansk, 80-211 - Gdansk/PL
  • 5 Respiratory Diseases Dept., KBC Zagreb - Clinic for Lung Diseases Jordanovac, 10000 - Zagreb/HR
  • 6 Second Department Of Medical Oncology And Clinical Trialsunit, Henry Dunant Hospital Centre, 115 26 - Athens/GR
  • 7 Lung And Thoracic Cancer Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1394P

Background

BRAF and cMET Exon 14 skipping are rare mutations of NSCLC. Opposite to other alterations, the preferred treatment sequencing in 1st and 2nd line is not clear.

Methods

We created an international registry for patients (pts) with advanced NSCLC harboring BRAF and cMET exon 14 skipping mutations, diagnosed from Jan 2017 until June 2022, excluding pts enrolled in clinical trials. Clinicopathologic and molecular data were collected, and treatment patterns were recorded. Clinical endpoints according to treatment assignment were assessed using Kaplan-Meier curves and Cox regression models.

Results

Data on 58 pts from 7 centers across 5 countries were included in the final analysis. Forty patients had cMET exon 14 skipping mutation and 18 had BRAF V600E mutation. Main characteristics: median age 66.7 (range: 36.0-91.0) years, female sex (48.0%), never or past smokers (71.0%), performance status 0-1 in (84.0%), adenocarcinoma (86.2%), stage IIIC - IV at diagnosis (82.2%), bone and brain metastasis (45.0%, and 21.0%, respectively). Mutations were uniformly diagnosed by NGS in all centers. Programmed death-ligand 1 TPS was <1% in 18%, 1-49% in 34% and >50% in 48% of cases. Fifty-three and 28 pts received 1st and 2nd line treatments, respectively, among which 52.8% received targeted therapy (TT) in 1st line and 53.5% in 2nd line. Overall response rate (ORR) and disease control rate (DCR) for 1st line treatment with TT vs. other (IO +/- CT ) was 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs 39.1% (p = 0.04), respectively. Type of treatment in 1st line (TT vs. IO +/- CT) affected Time to Treatment Discontinuation (TTD), 11.6 m vs. 4.6 m, p = 0.006. Overall survival for the whole group was 15.4 m and was not statistically influenced by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).

Conclusions

This real-world retrospective study suggests that TT in the 1st line is the preferred option for the treatment of pts with advanced NSCLC with BRAF and cMET exon 14 skipping mutations, as opposed to IO +/- CT, due to higher ORR and DCR, longer TTD and the fact that almost half of the patients did not receive 2nd line treatment. U Janzic and W. Shalata contributed equally to this study.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

U. Janzic: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, Roche, Pfizer; Financial Interests, Personal and Institutional, Advisory Board: MSD, BMS, Takeda, Amgen, Boehringer Ingelheim; Financial Interests, Institutional, Other: Novartis. W. Shalata, A. Agbarya, R. Dziadziuszko, M. Jakopovic: Financial Interests, Personal and Institutional, Advisory Board: Roche, AstraZeneca, MSD, Pfizer, Novartis, BMS. K. Szymczak: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Novartis, BMS, Amgen, Vipharm. G. Mountzios: Financial Interests, Personal and Institutional, Advisory Board: Roche, AstraZeneca, MSD, BMS, Gilead, Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mirati, Bioatlas. A. Pluzanski: Financial Interests, Personal and Institutional, Advisory Board: BMS, MSD, AstraZeneca, Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.